New anticancer molecules: Drugs for tomorrow?;Nouvelles molecules anticancereuses: Medicaments pour demain?

Bulletin du Cancer

Volumn 86, Issue 1, 1999, Pages 91-95

  Lavelle, François ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ERLOTINIB; FJ 5002; GEFITINIB; IMATINIB; ISIS 3521; LONAFARNIB; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; RPR 109881A; SEMAXANIB; TIPIFARNIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; TRANSFERASE;

ANIMAL CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLON CARCINOMA; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; GENE MUTATION; HUMAN; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PANCREAS CARCINOMA; REVIEW; TUMOR VASCULARIZATION; DRUG ANTAGONISM; FORECASTING;

ALKYL AND ARYL TRANSFERASES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FORECASTING; OLIGONUCLEOTIDES, ANTISENSE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 0032949320     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Zujewski J, Horak ID, Woestenborghs R, Chiao J, Cusack G, Kohler D, et al. Phase I trial of farnesyl-transferase inhibitor, R115777, in advanced cancer. Proc Am Assoc Cancer Res 1998 ; 39 : 270 (abstr. 1848).
2. Skrzat S, Angibaud P, Venet M, Sanz G, Bowden C, End D. R115777, a novel imidazole farnesyl transferase inhibitor (FTI) with potent oral antitumor activity. Proc Am Assoc Cancer Res 1998 ; 39 : 317 (abstr. 2169).
3. Venet M, Angibaud P, Sanz G, Poignet H, End D, Bowden C. Synthesis and in vitro structure-activity relationships of imidazolyl-2-quinolinones as farnesyl protein transferase inhibitors (FTI). Proc Am Assoc Cancer Res 1998 ; 39 : 318 (abstr. 2171).
4. Liu M, Lee S, Yaremko B, Chen J, Dell J, Nielsen L, et al. SCH 66336, an orally bioavailable tricyclic farnesyl protein transferase inhibitor, demonstrates broad and potent in viva antitumor activity. Proc Am Assoc Cancer Res 1998 ; 39 : 270 (abstr. 1843).
5. Kirschmeier P, Carr D, Gray K, James L, Patton R, McGuirk M, et al. SCH 66336, an orally bioavailable tricyclic farnesyl transferase inhibitor blocks anchorage-independent growth of Ras-transformed fibroblasts and human tumor cell lines. Proc Am Assoc Cancer Res 1998 ; 39 : 318 (abstr. 2175).
6. Przybranowski SA, Vincent PW, Lathia C, Hollembaek J, Quin J, Shuler KR, et al. In vivo evaluation of farnesyltransferase inhibitor, PD 169451 versus a panel of human tumor xenografts. Proc Am Assoc Cancer Res 1998 ; 39 : 269 (abstr. 1841).
7. Vrignaud P, Bello A, Bissery MC, Jenkins R, Hasnain A, Mailliet P, et al. RPR 130401, a non-peptidomimetic farnesyl transferase inhibitor with in vivo activity. Proc Am Assoc Cancer Res 1998 ; 39 : 560 (abstr. 1846).
8. Lavelle F. American Association for Cancer Research : progress and new hope in the fight against cancer. Exp Opin Inves Drugs 1997 ; 6 : 771-5.
9. Fry DW, Nelson JM, Slintak V, Keller PR, Loo J, Greis K, et al. Specific, irreversible inhibitors of the epidermal growth factor receptor (EGFR) family of tyrosine kinases. Proc Am Assoc Cancer Res 1998 ; 39 : 560 (abstr. 3806).
10. Vincent PW, Akinson BE, Zhou H, Dykes D, Leopold WR, Patmore SJ, et al. Characterization of the in vivo activity of a novel EGF receptor family kinase inhibitor, PD 169414. Proc Am Assoc Cancer Res 1998 ; 39 : 560 (abstr. 3807).
11. Meyer T, Zimmermann J, Geiger T, Mett H, Buchdunger E, Müller M, et al. CGP 60474, a protein kinase inhibitor with potent antitumor activity in vivo at well tolerated doses. Proc Am Assoc Cancer Res 1998 ; 39 : 558 (abstr. 3794).
12. Ruetz St, Woods-Cook K, Solf R, Meyer T, Zimmermann J, Fabbro D. Effect of CGP 60474 on cyclin dependent kinases (cdks), cell cycle progression and onset of apoptosis in normal and transformed cells. Proc Am Assoc Cancer Res 1998 ; 39 : 558 (abstr. 3796).
13. Werner JL, Kelsen DP, Karpeh M, Inzeo D, Barazzuol J, Sugarman A, et al. The cyclin-dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer. Proc Am Soc Clin Oncol 1998 ; 17 : 234a (abstr. 896).
14. Adams M, Thomas H. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol 1998 ; 17 : 217a (abstr. 838).
15. Grochow L, O'Reilly S, Humphrey R, Sundaresan P, Donehower R, Satorius S, et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566. Proc Am Soc Clin Oncol 1998 ; 17 : 213a (abstr. 822).
16. Liang H, Dey C, Chang A, Lu Y, Zhou X-H, Lapcevich R, et al. The importance of glycosylation and kringle 4 on the activity, of human Angiostatin™ protein. Proc Am Assoc Cancer Res 1998 ; 39 : 46 (abstr. 311).
17. Mac Donald N, Chang A, Zhou X-H, Luu K, Madsen J, Kough E, et al. In vitro and in vivo characterization of CHO expressed human Angiostatin™ kringles 1-3 and kringles 1-4 proteins. Proc Am Assoc Cancer Res 1998 ; 39 : 46 (abstr. 314).
18. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Ullrich A, et al. Effect of the Flk-1 antagonist SU5416 on tumor growth, angiogenesis and micro-hemodynamics. Proc Am Assoc Cancer Res 1998 ; 39 : 96 (abstr. 651).
19. Fong TAT, Shawver LK, App H, Sun L, Tang C, Rice A, et al. SU5416 : a potent and selective Flk-1/KDR kinase inhibitor that blocks Flk-1 phosphorylation, endothelial cell mitogenesis, and tumor growth. Proc Am Assoc Cancer Res 1998 ; 39 : 560 (abstr. 3811).
20. Rosen LS, Kabbinavar F, Rosen P, Mulay M, Quigley S, Hannah AL. Phase I trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 1998 ; 17 : 218a (abstr. 843).
21. O'Dwyer PJ, Stevenson JP, Gallagher M, Mitchell F, Friedland D, Rose L, et al. Phase I/pharmacokinetic/pharmacodynamic trial of Raf-1 antisense ODN (ISIS 5132, CGP 69846A). Proc Am Soc Clin Oncol 1998 ; 17 : 210a (abstr. 810).
22. Holmlund J, Nemunaitis J, Schiller J, Dorr A, Kisner D. Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc Am Soc Clin Oncol 1998 ; 17 : 210a (abstr. 811).
23. Nemunaitis J, Von Hoff DD, Holmlund J, Dorr A, Eckhardt SG. Phase I/pharmacokinetic (PK) trial of a protein kinase C-A antisense oligonucleotide, ISIS 3521 (CGP 64128A), administered thrice weekly. Proc Am Soc Clin Oncol 1998 ; 17 : 211a (abstr. 812).
24. Cobleigh MA, Vogel CI, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Efficacy and safety of herceptin™ (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998 ; 17 : 97a (abstr. 376).
25. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2′/MBC) markedly increases anticancer activity : a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998 ; 17 : 98a (abstr. 377).
26. Gordon MS, Talpaz M, Margolin K, Holmgren E, Sledge GW, Benjamin R, et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients (pts) with metastatic cancer. Proc Am Son Clin Oncol 1998 ; 17 : 210a (abstr. 809).
27. Fedorov OY, Salazar M, Kerwin SM, Han H, Hurley LH. High-field NMR studies of G-quadruplex binding by a telomerase-inhibiting compound. Proc Am Assoc Cancer Res 1998 ; 39 : 305 (abstr. 2084).
28. Naasani I, Seimiya H, Yamori T, Tsuruo T. Screening for antitelomerase agents with the aid of Compare analysis. Proc Am Assoc Cancer Res 1998 ; 39 : 567 (abstr. 3854).
29. Sessa C, Cuvier C, Caldiera S, Vernillet L, Pérard D, Riva A, et al. A phase I clinical and pharmacokinetic (PK) study of RPR 109881A, a new taxoid administered as a 1-hour infusion in patients (pts) with solid tumors. Proc Am Soc Clin Oncol 1998 ; 17 : 189a (abstr. 728).
30. Mooberry SL, Tien G, Plubrukarn A, Davidson BS. Discovery of new microtubule stabilizing agents from a marine sponge. Proc Am Assoc Cancer Res 1998 ; 39 : 166 (abstr. 1135).
31. Long BH, Wasserman AJ, Carboni JM, Oh S, Cornell LA, Peterson RW, et al. Tubulin polymerization induced by eleutherobin, a novel and potent cytotoxic agent. Proc Am Assoc Cancer Res 1998 ; 39 : 165 (abstr. 1128).